Form 4: iRhythm Holdings CBO/CLO Reports Stock Transactions

iRhythm Holdings' Chief Business and Legal Officer, Patrick Michael Murphy, reported the acquisition of shares from RSU vesting and subsequent sale to cover tax obligations.

Summary

• Patrick Michael Murphy, CBO and CLO of iRhythm Holdings, Inc., reported transactions involving common stock.
• Acquired 15,060 shares of common stock on February 24, 2026, at a price of $0.
• This acquisition resulted from the vesting of performance Restricted Stock Units (RSUs) granted on February 27, 2023, after performance conditions were met.
• Disposed of 7,805 shares of common stock on February 25, 2026, at a price of $135.4189 per share.
• The disposition was to cover tax withholding and remittance obligations related to the RSU vesting.
• Following these transactions, Murphy beneficially owns 60,536 shares of iRhythm Holdings, Inc. common stock.
• A holding company reorganization occurred on January 12, 2026, where iRhythm Holdings, Inc. became the successor issuer to iRhythm Technologies, Inc., with all outstanding shares and equity awards converting on a one-for-one basis.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as the vesting of performance RSUs indicates the achievement of company performance targets, reflecting positively on management's execution. The subsequent sale is a routine tax-related transaction.

Positives

• Performance conditions for Restricted Stock Units (RSUs) granted on February 27, 2023, were met, leading to the vesting of 15,060 shares.

Negatives

• No direct negatives identified from the reported transactions, as the share disposition was for tax withholding purposes.

Risks

• NA

Future Outlook

This filing, a Form 4, reports insider transactions and does not provide forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock ownership changes. The RSU vesting and subsequent tax-related sale are common occurrences for executives receiving equity compensation, reflecting a routine part of compensation plans rather than a discretionary investment decision.

Comparison to Industry Standards

• The RSU vesting and subsequent sale for tax purposes are standard practices in executive compensation across various industries, including medical technology. Companies like Medtronic (MDT) or Abbott Laboratories (ABT) also utilize performance-based equity awards for their executives, where similar tax-related dispositions occur upon vesting. This transaction aligns with typical compensation structures designed to incentivize long-term performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU vesting indicates performance targets were met, which could be viewed positively. The tax-related sale is a routine event and does not signal a change in management's long-term commitment.
• Employees: The vesting of performance RSUs for an executive may signal a healthy compensation structure tied to company performance.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the vesting of performance-based Restricted Stock Units and a subsequent sale to cover tax obligations. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or management's confidence. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information warranting a change in investment thesis.

Keywords

iRhythm Holdings, IRTC, Form 4, Insider Trading, Stock Transaction, RSU Vesting, Executive Compensation, Patrick Michael Murphy, Common Stock, Tax Withholding